PRISM BioLab provides PepMetics® (peptide mimetic small molecules) Technology for generating Hit and Lead compounds against Servier’s novel target. Read Full Press Release
アーカイブ: ニュース
独自開発のペプチド模倣技術を用いた低分子ライブラリーを提供
PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against Merck’s novel targets Read Full Press Release
PRISM BioLab、ドイツの製薬大手ベーリンガーインゲルハイムに対し独自開発のペプチド模倣技術を用いた低分子ライブラリーを提供
PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against Boehringer Ingelheim’s novel targets Read Full Press Release
合併に関するお知らせ
PRISM Pharma Co.,Ltd. (“Pharma”) and its wholly owned subsidiary, PRISM BioLab Co.,Ltd.(“BioLab”), have merged as of Octorber 1,2018. BioLab succeeds all Pharma’s rights and obligations. Because those two companies were operated as one by the same management, actual business will not change at all after this merger. PRISM BioLab Co., Ltd. President & CEO Dai...